# OKYO Pharma Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/OKYO Pharma Ltd). ## Overview OKYO Pharma Ltd is a U.S.-listed clinical-stage biopharmaceutical company focused on developing investigational therapies for neuropathic corneal pain and other anterior segment eye diseases. The company operates through drug development programs centered on urcosimod and related ophthalmology assets, with its ordinary shares listed on Nasdaq. ## Products & services • Investigational therapies for neuropathic corneal pain (NCP) • Urcosimod clinical development • Ophthalmology drug development for anterior segment eye diseases • Phase 3 clinical trial design and execution - **Neuropathic corneal pain therapies** (100%) — Clinical-stage drug candidates intended to treat NCP, a chronic ocular pain condition. - **Anterior segment eye disease therapies** (0%) — Investigational ophthalmic therapies aimed at diseases affecting the front part of the eye. - **Clinical development services** (0%) — Internal R&D, trial planning, and regulatory development work for pipeline assets. - Investigational therapies for neuropathic corneal pain (NCP) - Urcosimod clinical development - Ophthalmology drug development for anterior segment eye diseases - Phase 3 clinical trial design and execution ## Customers OKYO Pharma does not yet sell commercial products; its primary stakeholders are patients, ophthalmologists, and clinical investigators involved in its development programs. In a future commercialization scenario, the relevant customers would be physicians, specialty eye-care providers, and healthcare payers using approved ophthalmic therapies. For now, the company’s work is directed toward generating clinical evidence that supports eventual regulatory approval and physician adoption. - **Clinical trial patients with NCP** (primary) — Patients participating in studies of urcosimod and other investigational eye therapies. - **Ophthalmology investigators and trial sites** (primary) — Specialist physicians and clinical sites that recruit patients and generate trial data. - **Regulatory authorities** (primary) — Agencies reviewing safety and efficacy data needed for advancement to approval. - **Future ophthalmology prescribers** (secondary) — Eye specialists who could prescribe approved treatments if development succeeds. - Patients with neuropathic corneal pain enrolled in clinical trials - Ophthalmologists and eye-care investigators running studies - Regulators and ethics committees reviewing trial data - Future prescribing physicians in specialty ophthalmology markets - Future payers and health systems if products reach approval ## Geography OKYO Pharma is headquartered in London and operates as a foreign private issuer listed in the United States on Nasdaq. Its development activities are organized around global clinical trial execution, with the company explicitly planning a global Phase 3 study for urcosimod. As a clinical-stage biotech, its geography matters mainly through trial-site selection, regulatory pathways, and access to capital markets rather than manufacturing footprint. - Headquartered in London, United Kingdom - Listed on Nasdaq Capital Market in the United States - Clinical development described as global in scope - Trial geography will affect patient recruitment and regulatory review ## Strategy OKYO Pharma’s core strategy is to advance urcosimod through late-stage clinical development for neuropathic corneal pain and build evidence for potential registration. The company is also strengthening its ophthalmology-focused leadership and maintaining access to capital so it can execute longer-duration clinical programs. Its commercial value depends on generating differentiated clinical data in a niche eye-disease category with limited approved treatment options. - **Complete Phase 3 development of urcosimod** (short-term) — Late-stage data are the main value-creation step for a clinical-stage biotech. - **Strengthen ophthalmology pipeline positioning** (medium-term) — A focused eye-disease portfolio can support follow-on development beyond the lead program. - **Preserve funding for development execution** (short-term) — Clinical trials and regulatory work require ongoing capital before any product revenue exists. - Advance urcosimod into and through Phase 3 development - Target neuropathic corneal pain as the lead indication - Expand into adjacent anterior segment eye diseases - Secure funding for multi-country clinical execution - Build clinical and regulatory credibility in ophthalmology ## Risks OKYO Pharma is exposed to the usual clinical-stage biotech risks: trial failure, safety or efficacy concerns, regulatory delays, and the possibility that a lead asset never reaches commercialization. Because it has no marketed products, its value is also highly dependent on external financing and on the ability to generate positive clinical data in a narrow ophthalmology indication. - **Late-stage clinical failure** [critical] — The company’s value depends on positive Phase 3 data for urcosimod. - **Regulatory approval delay or denial** [high] — Even successful trials require regulator acceptance of the evidence package. - **Dilution from future capital raises** [high] — Clinical-stage companies typically fund operations through equity issuance. - **Reimbursement and pricing pressure** [medium] — Even approved ophthalmic drugs can face coverage limits and cost controls. - Clinical trial failure could halt the lead program - Safety or efficacy issues could prevent approval - Dependence on external capital before product sales begin - Regulatory timelines may be longer than expected - Ophthalmology reimbursement uncertainty can affect future uptake ## Accounting As a clinical-stage biotech, OKYO Pharma’s reported results are dominated by R&D and G&A spending rather than product revenue. Investors should watch how development costs, equity raises, and share-based payments affect the income statement and cash position, along with tax items such as UK R&D relief. If pipeline assets fail to progress, capitalization or impairment judgments would become more important, though no commercial revenue recognition issues currently dominate the model. - **Research and development expense** — Directly affects operating loss and comparability between periods - **General and administrative expense** — Can increase as headcount and compliance needs grow - **Equity financing and dilution** — Affects per-share analysis and ownership dilution - **UK R&D tax relief** — Can offset cash burn and influence tax line items - R&D expense is the main operating cost driver - G&A rises with public-company compliance and staffing - Equity raises affect dilution and cash runway - UK R&D tax relief can offset some development costs - No product revenue yet, so revenue recognition is not a core issue --- *Last updated: 2026-09-28T12:13:30.082921+00:00*